Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N06AX21

Duloxetine Viatris (previously Duloxetine Mylan)(duloxetine)

Neuralgia;Diabetic Neuropathies;Depressive Disorder, Major;Anxiety Disorders

Marketing Authorisation Holder: Viatris Limited

EMA Authorisation: 19/06/2015

INN: duloxetine

Indication

Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Viatris is indicated in adults

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Duloxetine Viatris (previously Duloxetine Mylan) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.